Multicenter Expanded Access Protocol of ATA129 for Subjects with Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There are No Appropriate Alternative Therapies
Study of EBV-Cytotoxic T Lymphocytes (EBV-CTLs) in Patients with Epstein-Barr Virus-Associated Viremia or Malignancies
Sponsor: Atara Biotherapeuticcs, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR0039
U.S. Govt. ID: NCT02822495
Contact: Ran Reshef, MD: 646-317-4805 /
Additional Study Information: Epstein-Barr Virus (EBV) is the virus that causes mononucleosis, also known as mono. Almost all adults have had EBV. For most people, EBV never causes a health problem. However, when their immune system is not working properly (people who have had a transplant and those who have immune disorders), EBV can cause certain diseases where cells grow abnormally. Special immune cells, called T cells, have been made that could attack the abnormal cells. If you participate, you will receive special immune cells called EBV-Cytotoxic T Lymphocytes (EBV-CTLs), made in the laboratory starting with cells from a healthy person who is immune to EBV. Treatment for you will be selected for you from a bank of frozen EBV-CTLs, based on sharing certain human leukocyte antigens (HLAs), which the EBV-CTLs need to work. EBV-CTLs have been studied previously in 2 trials. The purpose of this study is to allow you to be treated with EBV-CTLs if you have had a transplant or immune disorder and an EBV disease and there is no other satisfactory treatment options or you do not qualify to take part in other EBV-CTL studies. Your participation will help us to understand about responses to treatment and any side effects that may occur in research subjects/participants treated with EBV-CTLs.
This study is closed
Ran Reshef, MD
Do You Qualify?
Have you been diagnosed with lymphoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Ran Reshef, MD